These authors also show that partial inhibition of Wnt/pathway by R-etodolac shortened the in vitro survival of the CLL cells, contrariwise to SB-216763 (GSK-3β inhibitor) treatment that enhances CLL survival. The gene discussed is GSK3B; the disease is B-cell chronic lymphocytic leukemia.